Table 4.
The Pharmacokinetic Parameters of Celecoxib in Different Forms (n = 6)
| Parameters | Celebrex® | CXB-NLCs | HA-NLCs |
|---|---|---|---|
| AUC0-t (h∙ng∙mL−1) | 12,917.36 ± 1013.76 | 18,371.69 ± 5585.27* | 19,985.26 ± 2207.79** |
| AUC0-∞ (h∙ng∙mL−1) | 19,724.04 ± 10,814.67 | 19,662.54 ± 6320.697 | 24,893.24 ± 432.93 |
| Cmax (ng∙mL−1) | 1005.67 ± 240.44 | 1659.09 ± 152.57** | 1612.13 ± 268.63** |
| Tmax (h) | 6.0 ± 3.6 | 2.5 ± 1.0 | 4.3 ± 2.9 |
| T1/2 (h) | 8.07 ± 2.54 | 5.67 ± 1.36 | 9.38 ± 4.71 |
| MRT0-t (h) | 8.91 ± 1.38 | 7.38 ± 1.16 | 7.95 ± 0.74 |
| Clz/F (L∙h−1∙kg−1) | 0.30 ± 0.10 | 0.28 ± 0.10 | 0.21 ± 0.04 |
| Vz/F (L∙kg−1) | 3.33 ± 1.18 | 2.14 ± 0.10 | 2.64 ± 0.99 |
| Relative bioavailability (%) | — | 142.22 ± 43.24% | 154.72 ± 17.19% |
Note: Compared with Celebrex® group, *P<0.05; **P<0.01.